Dottikon shares have fallen to a 15-month low, trading at 259 Swiss francs after a month of continuous declines. The level was last reached on June 2, 2025. The pharma supplier’s stock had reached a record 396 Swiss francs at the end of May 2026 before reversing sharply.
The decline followed the release of annual results that analysts described as disappointing. The company’s operational performance came in below expectations, and the share price fell 21% in the aftermath. A ZKB analyst had characterized the drop as a pause rather than a trend reversal, assigning a fair value of 460 Swiss francs per share and forecasting a renewed record run. That rebound has not materialized.
Investors are now focused on Dottikon’s recent capital investments and capacity expansion. The company has built a new chemical multi-purpose plant for large-scale production of active pharmaceutical ingredients, an asset that could support faster growth in coming years. ZKB expects revenue to rise 22.8% in fiscal 2026/2027 and 27.5% in fiscal 2027/2028.
The next catalyst is the half-year report, scheduled for November 27. Risk-tolerant investors may view the current price as an opportunity to position ahead of potentially strong results, although the stock’s near-term direction remains tied to the upcoming figures.
